Kiniksa (KNSA) Chief Strategy Officer named as insider in Form 3

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc filed an initial Form 3 for Dhiraj H. Malkani, who serves as Chief Strategy Officer. This filing identifies him as a reporting insider under SEC rules but does not describe any specific share transactions or option exercises.

Key Terms

Form 3, Chief Strategy Officer, reporting insider

3 terms

Form 3 regulatory

"Kiniksa Pharmaceuticals International, plc filed an initial Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Strategy Officer financial

"Dhiraj H. Malkani is identified with the title Chief Strategy Officer"

A chief strategy officer (CSO) is the senior executive who crafts a company’s long-term plan and decides which markets, products, partnerships, or investments to prioritize—think of them as the company’s navigator plotting the course. Investors pay attention because the CSO shapes where the company will grow, what risks it will take, and how it will deploy resources; strong strategic direction can improve future revenue and value, while poor choices can weigh on returns.

reporting insider regulatory

"The filing identifies him as a reporting insider under SEC rules"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/06/2026 - 04:37 PM Accepted by SEC EDGAR 07/06/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Malkani Dhiraj H

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2026

3. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF STRATEGY OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Douglas Barry, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Kiniksa (KNSA) Form 3 filing for Dhiraj H. Malkani show?

The Form 3 filing records Dhiraj H. Malkani as a reporting insider of Kiniksa as Chief Strategy Officer. It is an initial statement of beneficial ownership and does not list any specific share transactions or option exercises.

Who is the reporting person in the Kiniksa (KNSA) Form 3?

The reporting person is Dhiraj H. Malkani, identified as an officer of Kiniksa with the title Chief Strategy Officer. The filing confirms his status as an insider subject to ongoing SEC ownership and trading disclosure requirements.

Does the Kiniksa (KNSA) Form 3 include any buy or sell transactions?

No, the Form 3 data show zero buy, sell, acquire, dispose, or exercise transactions. It functions purely as an initial registration of insider status rather than a report of recent trading activity in Kiniksa shares or derivatives.

What transaction summary details are reported in the Kiniksa (KNSA) Form 3?

The transaction summary lists counts and share amounts for buys, sells, exercises, gifts, tax withholdings, and restructurings, all at zero. It also notes a neutral net buy/sell direction, indicating no recorded trading activity in this filing.

Does the Kiniksa (KNSA) Form 3 disclose any derivative positions for the officer?

The derivative section is empty in this Form 3, so no options, warrants, or other derivative securities are listed. The filing focuses solely on establishing Dhiraj H. Malkani as a reporting insider without detailing derivative holdings.